| Literature DB >> 25789036 |
Yizi Cong1, Guangdong Qiao1, Haidong Zou1, Jun Lin1, Xingmiao Wang1, Xiaohui Li1, Yalun Li1, Shiguang Zhu1.
Abstract
Nine cases of infiltrating cribriform carcinoma (ICC) of the breast are reported and the clinicopathological features, particularly the imaging findings, are analyzed in the present study. Sonograms revealed that all masses exhibited a hypoechoic internal echo texture (9/9) and that a number of masses presented with an irregular shape (8/9), obscure boundary (5/9), partially microlobulated (5/9) or well-circumscribed (4/9) margins, and an inhomogeneous echo (8/9). Mammographic imaging revealed increased radiological density masses (6/8), and sand-like calcification was not observed in all patients. In two patients, the tumors were mammographically occult. Magnetic resonance imaging performed on one patient revealed a slightly high signal intensity on fat-saturated T1- and T2-weighted images. Following contrast enhancement, a homogeneous early enhancement was revealed with a quick ascent and quick descent time-density curve. Immunohistochemistry revealed that all ICCs expressed estrogen receptor and progesterone receptor, but that none were positive for human epidermal growth factor receptor 2. The Ki-67 labeling index was 3.75% (range, 2-5%) in the tumor tissue. Four patients were treated with mastectomy and the others with breast-conserving surgery. Six clinically node-negative patients underwent sentinel lymph node biopsy; three then received axillary lymph node dissection. Following surgery, three patients received adjuvant chemotherapy, radiotherapy and hormonal therapy, respectively. With a median follow-up time of 38 months (range, 4-70 months), one patient developed local recurrence following breast-conserving surgery; axillary lymph nodes and distant metastases were not observed. This study confirms that this type of carcinoma has unique biological characteristics and a favorable prognosis, but that it remains possible to experience local recurrence.Entities:
Keywords: breast; invasive cribriform carcinoma; magnetic resonance imaging; mammography; prognosis; ultrasound
Year: 2015 PMID: 25789036 PMCID: PMC4356388 DOI: 10.3892/ol.2015.2972
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Patient characteristics.
| Case no. | Age, years | Menopause | Family history | Laterality | Location (quadrant) | Tumor size, cm | Surgery | Metastatic LNs, n | TNM stage | Immunohistochemistry | Chemotherapy | Radiotherapy | Endocrine therapy | Follow-up, months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 49 | No | Yes | Right | Superior external | 1.5 | BCS+ALND | 5 | IIIA | ER(++), PR(+), HER2(+) | CEF | Yes | None | 28 |
| 2 | 40 | Yes | Yes | Right | Superior external | 1.7 | BCS+SLNB | 0 | I | ER(++), PR(++), HER2(−) | None | Yes | Tamoxifen (6 months) | 70 |
| 3 | 41 | No | No | Right | Superior external | 1.1 | BCS+SLNB+ALND | 1 | IIA | ER(++), PR(++), HER2(−) | None | None | None | 69 |
| 4 | 69 | Yes | No | Right | Superior internal | 1.0 | BCS+SLNB | 0 | I | ER(+++), PR(+++), HER2(−), p53(−), Ki-67 3%, CK5/6(−), CD10, p63 focal(+), 34βE12(+) | None | None | None | 48 |
| 5 | 68 | Yes | No | Right | Superior external | 3.2 | BCS+ALND | 0 | IIA | ER(+++), PR(+++), HER2(++) | None | Yes | Letrozole (17 months) | 17 |
| 6 | 46 | No | Yes | Left | Superior internal | 2.5 | M+SLNB+ALND | 1 | IIB | ER(+), PR(+++), HER2(−) | TE | None | Unknown | 4 |
| 7 | 79 | Yes | No | Left | Superior external | 3.0 | M+ALND | 1 | IIB | ER(+), PR(++), HER2(−) | None | None | None | Unknown |
| 8 | 55 | No | Yes | Left | Inferior external | 2.0 | M+SLNB+ALND | 2 | IIA | ER(+), PR(++), HER2(−), p53(−), Ki-67 5% | CEF | None | None | 53 |
| 9 | 71 | Yes | Yes | Left | Inferior internal | 1.2 | M+SLNB | 0 | I | ER(+), PR(+), HER2(−), p53 focal(+), Ki-67 2% | None | None | Arimidex (25 months) | 25 |
Immunohistochemistry revealed HER2(++), fluorescence in situ hybridization confirmed HER2(−);
four cycles;
six cycles.
LNs, lymph nodes; BCS, breast-conserving surgery; M, mastectomy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor-node-metastasis; CEF, cyclophosphamide, epirubicin and fluorouracil; TE, docetaxel and epirubicin.
Figure 1Case 5 from Table I (A) Oblique and (B) axial mammography findings. A high uneven density mass measuring 2.5 cm, with fuzzy boundaries, was observed in the superior external quadrant of the right breast. Enlarged lymph nodes were not observed in the right axilla. (C) Echography imaging revealed a low uneven echo mass range of 2.4×2.0 cm that was lobulated with clear boundaries, crude edges and an irregular shape. Color Doppler flow imaging revealed a rich blood flow signal in and around the mass. (D) Pathological results revealed invasive cribriform carcinoma of the breast (hematoxylin and eosin staining; magnification, ×100).
Figure 2Case 4 from Table I. (A and B) Magnetic resonance imaging findings. The mass measuring 1.3×0.9 cm exhibited a slightly high signal intensity on fat-saturated T1- and T2-weighted images. Following contrast enhancement, (A) a homogeneous early enhancement was revealed with (B) a quick ascent and descent time-density curve. (C) Echography imaging revealed that the low echo mass range of 1.2×0.7 cm was less regular in morphology with a well-defined margin and uneven echo. Color Doppler flow imaging detected no blood flow signal in and around the mass. (D) Pathological results revealed invasive cribriform carcinoma of the breast (hematoxylin and eosin staining; magnification, ×100).